Pharma Focus Asia
KP - Sustainable Packaging Solutions

NouvNeu001 Hits Milestone with Successful Dosing of First Patient in iRegene Therapeutics' Multicenter Clinical Trial for Novel Parkinson's Disease Therapy

Tuesday, February 06, 2024

iRegene Therapeutics Co., Ltd (iRegene) recently made an important announcement regarding the progress of NouvNeu001, their innovative product. They reported the completion of dosing for the first patient at Beijing Hospital, marking the successful conclusion of the observation period.

This achievement is part of a Phase I/II clinical trial designed to evaluate NouvNeu001's safety, tolerability, and efficacy in treating moderate to advanced Parkinson's disease. The trial has begun at both Beijing Hospital and Zhongnan Hospital, with the first patient completing dosing.

Dr. Cai, iRegene's Chief Medical Officer, highlighted the significance of this milestone in the company's development.

NouvNeu001 is a chemically induced human dopaminergic neuron precursor derived from iPSC, wholly owned by iRegene. It is the world's first iPSC-based and chemically induced universal cell therapy product. NouvNeu001 is designed to optimize neuronal subtypes through chemical induction, establishing connections with existing neurons upon transplantation to enhance cellular secretion functions and address the original lesion, offering comprehensive therapeutic effects.

The National Medical Products Administration (NMPA) of China approved the Phase I/II clinical trial of NouvNeu001 on August 2, 2023. The trial, aimed at evaluating safety, tolerability, and efficacy in treating moderate to advanced Parkinson's disease, commenced successfully at Beijing Hospital in early January 2024. More details about the trial can be found on clinicaltrials.gov (NCT#06167681).

iRegene Therapeutics is a pioneering biotech company focused on utilizing "AI + chemical induction" for cell-specific functional remodeling. Leveraging this platform, iRegene has developed a robust pipeline of universal iPSC-derived products. The company is dedicated to advancing universal cell therapy products and introducing novel treatment options for traditionally challenging neurodegenerative diseases such as Parkinson's disease and blindness.

 

Source: prnewswire.com

Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024Equinix accelerated medical research...CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?